ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tofacitinib in Refractory Dermatomyositis (STIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03002649
Recruitment Status : Recruiting
First Posted : December 26, 2016
Last Update Posted : February 11, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis.

Condition or disease Intervention/treatment Phase
Dermatomyositis Drug: Tofacitinib Phase 1

Detailed Description:
Dermatomyositis (DM) is a rare, progressively debilitating disorder that affects the muscle (causing weakness) and skin (causing a rash) in most affected patients. DM can also involve multiple body systems including the lungs, joints, gut and heart. Therapy for DM involves administering corticosteroids, typically with an immunosuppressive agent, but treatment options for refractory DM are very limited. This research is being done to determine the safety and effectiveness of a Janus kinase (JAK) inhibitor called Tofacitinib in adults with active, treatment-refractory dermatomyositis. The investigators will also look for specific biomolecular changes in blood, skin, and muscle when it is exposed to Tofacitinib. Tofacitinib is approved by the Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis. The study aim is to conduct a 12-week, open-label, pilot study with up to 10 patients who have refractory DM to assess whether a JAK inhibitor effectively and safely reduces the symptoms of DM in both the skin and muscle. This study consists of up to 9 study visits over 6 months. There is an optional treatment extension period of 4 weeks. All subjects will undergo follow-up assessments 4 weeks after stopping treatment. Results from this study will contribute to the design of future trials that will further define the role of JAK inhibitors in the treatment of patients with dermatomyositis.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients
Study Start Date : January 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : June 2020


Arm Intervention/treatment
Experimental: Tofacitinib
All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
Drug: Tofacitinib
Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
Other Names:
  • Xeljanz XR
  • Tofacitinib citrate




Primary Outcome Measures :
  1. Number of participants who achieve International Myositis Assessment and Clinical Studies (IMACS) Definition of Improvement (DOI) [ Time Frame: Up to 12 weeks ]
    IMACS DOI is 3 of any of the 6 core set measures (CSM) improved by ≥ 20%, with no more than 2 CSM worsening by ≥25% (worsening measure cannot include the manual muscle testing)


Secondary Outcome Measures :
  1. Change from baseline in CDASI activity score [ Time Frame: Up to 16 weeks ]
  2. Safety and tolerability of tofacitinib as assessed by frequency of adverse events reported and observed [ Time Frame: Up to 16 weeks ]
  3. Safety and tolerability of tofacitinib as assessed by incidence of adverse events reported and observed [ Time Frame: Up to 16 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Study subjects must meet the following criteria:

  • Definite or probable dermatomyositis by Bohan and Peter Criteria at least 6 months before screening
  • Active skin disease as defined by a CDASI score of at least 5
  • Skin biopsy proven disease
  • Although not mandatory, patients with muscle weakness are eligible for enrollment. Those with active muscle disease must have a Manual Muscle Testing (MMT-8) score < 142 out of 150
  • Age > 18
  • Refractory myositis is defined by active disease despite a 12 week trial of steroids and with failure of response to at least prednisone and 1 other first line immunosuppressive agents (e.g. methotrexate, mycophenolate mofetil, or azathioprine) OR have demonstrated significant toxicity or intolerance to such therapies
  • Maximum prednisone dose allowed will be 20mg/daily at time of entry to study provided that the dose has been stable for at least 2 weeks prior to baseline. Patients should not have received a daily therapy of more than 80mg of prednisone equivalent within 8 weeks prior to study entry
  • Negative cancer screening conducted in the 6 months prior to screening visit
  • Washout of immunosuppressive agents will be as follows:

    1. Azathioprine, mycophenolate, tacrolimus: 12-16 weeks prior to first dose of study drug;
    2. Rituximab: 12 months;
    3. Intravenous Immunoglobulin (IVIg): 3 months;
    4. Cyclophosphamide: 1 year;
    5. Methotrexate: 12-16 weeks.
  • Women of child-bearing potential must have negative pregnancy test and be willing to undergo urine pregnancy testing at every on-site visit for the duration of the study
  • Must provide informed consent
  • Must be willing and able to comply with the requirements of the protocol

Exclusion Criteria:

The presence of any of the following excludes subject participation in the study:

  • Use of other investigational drugs at the time of enrollment
  • History of hypersensitivity to any of the study drugs or drugs of similar chemical classes
  • DM patients having overlap myositis attributable to other causes such as scleroderma, arthritis, statin myopathy, steroid induced myopathy and/or significant organ damage e.g. lupus nephritis, central nervous system are present
  • Late stage DM whose muscle weakness, according to the Investigator, could be attributable to muscle damage rather than myositis disease activity
  • Patients with other types of myositis or myopathies: polymyositis, paraneoplastic myositis, inclusion body myositis, metabolic or drug induced myopathy, dystrophies
  • Inclusion body myositis, Juvenile dermatomyositis or polymyositis, or myositis in overlap with other rheumatic diseases such as lupus, scleroderma, Sjogren's, or vasculitis
  • Patients with advanced clinically symptomatic interstitial lung disease
  • Pregnancy or breast-feeding patients
  • History of bowel rupture or inflammatory bowel diseases
  • History of tuberculosis or mycobacterial infections
  • Recent infection in the past 4 weeks before entry of study
  • History of any malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
  • Active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis B, Hepatitis C infection
  • Diverticulitis or ulcers in stomach or intestines
  • Evidence of any other acute or chronic infectious diseases
  • Have received any live or live attenuated vaccines (including varicella or measles) within 2 months prior to study enrollment
  • Patients with any of the following hepatic conditions prior to study: (a) history of chronic liver or biliary disease, (b) total conjugated bilirubin greater than 1.5 times upper limits of normal (ULN) range, unless in the context of Gilbert's syndrome, (c) alkaline phosphatase greater than 1.5 times the ULN range, (d) aspartate transaminase (AST), alanine transaminase (ALT) greater than 3 times the ULN if the elevation of AST or ALT, according to the investigator, is attributable to liver disease. Patients with elevated AST/ALT due to myositis disease activity are eligible, (e) Gamma-glutamyltransferase (GGT) greater than 3 times the ULN range
  • Current or recent history of uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease
  • Blood dyscrasias within 3 months prior to the first dose of study medication, including confirmed:

    1. Hemoglobin <9 g/dL or Hematocrit <30%;
    2. White blood cell count <3.0 x 109/L;
    3. Absolute neutrophil count <1.2 x 109/L;
    4. Platelet count <100 x 109/L.
  • Estimated glomerular filtration rate (GFR) <40 ml/min based on Cockcroft-Gault calculation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03002649


Contacts
Contact: Julie Paik, MD 410-550-1741
Contact: Sherry Leung 410-550-6962

Locations
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21224
Contact: Julie Paik, MD    410-550-1741      
Principal Investigator: Julie Paik, MD         
Sponsors and Collaborators
Johns Hopkins University
Pfizer
Investigators
Principal Investigator: Julie Paik, MD Johns Hopkins University

Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT03002649     History of Changes
Other Study ID Numbers: IRB00084227
First Posted: December 26, 2016    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Johns Hopkins University:
Dermatomyositis
Tofacitinib
Refractory dermatomyositis

Additional relevant MeSH terms:
Dermatomyositis
Polymyositis
Myositis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action